Form 4: Aardvark Therapeutics CMO Manasi Jaiman Granted Significant Stock Options

Aardvark Therapeutics, Inc.'s Chief Medical Officer, Manasi Jaiman, was granted 126,999 stock options with an exercise price of $11.29, vesting over four years.

Summary

• Manasi Jaiman, Chief Medical Officer of Aardvark Therapeutics, Inc. (AARD), was granted 126,999 stock options.
• The options have an exercise price of $11.29 per share.
• The grant date for the earliest transaction was June 11, 2025.
• The options are for the right to buy 126,999 shares of Aardvark Therapeutics Common Stock.
• The vesting schedule dictates that 1/4th of the shares will vest on June 11, 2026, with the remaining 3/4ths vesting in monthly installments of 1/48th thereafter, contingent on continuous service.
• The options expire on June 11, 2035.
• This transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive sign for retention and alignment of interests, indicating confidence in the company's future. It's a standard compensation practice, so not overwhelmingly positive, but certainly not negative.

Positives

• The grant of stock options to the Chief Medical Officer aligns her incentives with long-term shareholder value.
• The 10b5-1 plan indicates a pre-arranged transaction, reducing concerns about opportunistic trading.
• The long vesting period (4 years) encourages retention of key management.

Negatives

• Potential dilution for existing shareholders if options are exercised in the future, though this is standard for equity compensation.

Risks

• The vesting of options is subject to the Reporting Person's continuous service, meaning forfeiture if employment ceases.
• The value of the options is dependent on the future stock price of Aardvark Therapeutics, Inc. exceeding the exercise price of $11.29.

Future Outlook

The stock option grant with a long-term vesting schedule suggests the company's strategy to retain key executive talent and align their interests with the company's long-term performance and growth.

Industry Context

Equity compensation, particularly through stock options with vesting schedules, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives, especially in companies like Aardvark Therapeutics that are likely in development phases and rely heavily on talent for future success.

Comparison to Industry Standards

• The grant of stock options to a Chief Medical Officer with a four-year vesting schedule (1/4th after one year, then monthly) is a common and competitive compensation structure within the biotech and pharmaceutical sectors, comparable to practices at companies like Moderna, BioNTech, or smaller clinical-stage biotechs, designed to ensure long-term commitment and performance alignment.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also benefit from incentivized management performance.
• Employees: Standard equity compensation practices can positively influence employee morale and retention.

Next Steps

• Continued monthly vesting of stock options for Manasi Jaiman, subject to continuous service, following the initial one-year cliff vesting on June 11, 2026.

Key Dates

Recommendation

Keywords

Aardvark Therapeutics, AARD, SEC Form 4, Stock Options, Equity Compensation, Manasi Jaiman, Chief Medical Officer, Insider Trading, Rule 10b5-1, Vesting Schedule